CM
REGN icon

Capula Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Capula Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$386K Hold
500
– – ﹤0.01% 586
2025
Q4 		$386K Buy
500
+100
+25% +$67.9K ﹤0.01% 434
2025
Q3 		$225K Buy
400
+100
+33% +$56.5K ﹤0.01% 581
2025
Q2 		$158K Hold
300
– – ﹤0.01% 421
2025
Q1 		$190K Buy
+300
New +$206K ﹤0.01% 529
2024
Q4 		– Sell
-200
Closed -$210K – 568
2024
Q3 		$210K Buy
+200
New +$223K ﹤0.01% 369
2024
Q2 		– Sell
-200
Closed -$192K – 622
2024
Q1 		$192K Buy
+200
New +$190K ﹤0.01% 414
2023
Q4 		– Sell
-2,000
Closed -$1.65M – 541
2023
Q3 		$1.65M Buy
+2,000
New +$1.57M 0.03% 161
2022
Q2 		– Sell
-17,500
Closed -$12.2M – 363
2022
Q1 		$12.2M Buy
+17,500
New +$11.1M 0.17% 117
2021
Q2 		– Sell
-13,400
Closed -$6.34M – 858
2021
Q1 		$6.34M Buy
+13,400
New +$6.52M 0.13% 180

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Capula Management's REGN Position: Q4 2025 in Review

Capula Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2025, closing a stake of 181 shares — an estimated $123K sold.

Capula Management first reported a position in REGN in Q1 2021 and held it in 8 quarters. The position peaked at $4.39M in Q1 2021. 1,385 funds tracked by Wall St. Rank hold REGN as of Q4 2025.

  • Capula Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Capula Management sold 181 Regeneron Pharmaceuticals shares in Q4 2025, an estimated $123K.
  • Capula Management first reported a position in Regeneron Pharmaceuticals in Q1 2021 and held it in 8 quarters.
  • Capula Management's Regeneron Pharmaceuticals position peaked at $4.39M in Q1 2021.
  • 1,385 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2025.

Based on Capula Management's 13F filing for Q4 2025, filed 13 Feb 2026.